VEGFR/PDGFR kinase inhibitors (Cotinga Pharmaceuticals)

N/A

Report date: 2025/03/20 09:51:15
NME

Base Information

Drug NameVEGFR/PDGFR kinase inhibitors (Cotinga Pharmaceuticals)
Drug Alias NameVEGFR/PDGFR kinase inhibitors (Critical Outcome Technologies)COT604-M06.2COT601-M06.1
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor antagonistsPlatelet-derived growth factor receptor inhibitors
TargetsPlatelet-derived growth factor receptorVascular endothelial growth factor receptor
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCotinga Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesCotinga Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A